Fertility Drugs Global Market Report 2024

The fertility drugs market size has grown steadily in recent years. It will grow from $2.63 billion in 2023 to $2.73 billion in 2024 at a compound annual growth rate (CAGR) of 3.7%. The expansion observed in the historical period can be attributed to several factors including the rise in infertility rates, advancements in reproductive medicine, the widespread adoption of assisted reproductive technologies (ART), and the trend of delayed childbearing among individuals and couples.

The fertility drugs market size is expected to see steadily grown in the next few years. It will grow to $3.11 billion in 2028 at a compound annual growth rate (CAGR) of 3.3%. The projected growth in the forecast period is expected to be driven by factors such as the aging population, lifestyle-related factors influencing fertility, the continued advancement and utilization of assisted reproductive technologies (ART), and the emergence of personalized medicine in fertility treatments. Key trends anticipated for this period encompass further advancements in ART, the development of ovulation-inducing medications, and the utilization of hormone therapy within fertility treatments.

The escalating demand for fertility drugs finds its impetus in the surging global rates of infertility, defined as the inability to conceive after a year of continuous attempts. This market growth is propelled by the increased prevalence of physiological and hormonal issues, along with lifestyle and environmental factors contributing to infertility in both men and women. A report from the World Health Organization in April 2023 estimates that millions worldwide, accounting for 1 in 6 adults or roughly 17.5% of the global adult population, will grapple with infertility, substantially impacting families and communities. Consequently, the burgeoning cases of infertility globally are driving the increased need for fertility drugs, thereby augmenting growth in the fertility drug market.

Anticipated growth in the fertility drugs market is further propelled by the mounting prevalence of obesity, a condition significantly associated with infertility in men and women. This trend stems from the imperative for specialized treatments, augmented awareness, supportive governmental policies, and ongoing research endeavors aimed at addressing fertility challenges linked to obesity. Data from the World Heart Federation in March 2023 reveals a staggering 2.3 billion individuals, both adults and children, affected by obesity or overweight conditions globally. Projections indicate an upward trend, with estimates foreseeing a rise to 2.7 billion by 2025. Thus, the burgeoning prevalence of obesity serves as a driving force propelling growth within the fertility drugs market. Companies within the fertility drugs sector are strategically focused on introducing user-friendly solutions for advanced infertility treatments, exemplified by self-administration fertility solutions. These innovations aim to alleviate discomfort and simplify the process of daily injections, particularly for women. An instance is the August 2021 launch of the Pergoveris Pen by Merck Specialties in India, designed for women with severe FSH and LH deficiencies. This self-administration system, comprising freeze-dried powder and solvent, minimizes reconstitution errors and ensures precise delivery, enhancing accessibility for patients managing infertility treatments.

Major players in the fertility drugs market are launching comprehensive campaigns centered around fertility care, aiming to secure competitive advantages. These campaigns, designed to raise awareness and educate the public on fertility-related issues, treatments, and reproductive health, play a crucial role in safeguarding access to fertility care. Pinnacle Fertility's August 2022 initiative, the Save IVF campaign in the US, is a prime example. Focused on potential legislation affecting family-building treatments like IVF in the absence of federal protection, this campaign advocates for preserving fertility care access. By mobilizing communities and encouraging individuals to support the cause through the #SaveIVF Pledge, Pinnacle Fertility seeks to protect fertility treatments' accessibility and combat legislative threats.

In March 2023, Sumitovant Biopharma Ltd., a US-based biopharmaceutical company, finalized the acquisition of Myovant Sciences Ltd. For an undisclosed sum. This strategic acquisition amplifies Sumitovant's collaborative capabilities, resources, and expertise, enabling them to effectively tackle unmet needs in women's health and prostate cancer. The combined entity aims to advance their joint pipeline's development, extending the reach of their distinct therapies to benefit diverse patient communities. Myovant Sciences Ltd., a US-based biotechnology firm, specializes in developing and commercializing novel treatments for women's diseases and endocrine disorders. Their focus areas include addressing conditions like heavy menstrual bleeding associated with uterine fibroids and female infertility. This acquisition marks a pivotal step for both companies in bolstering their offerings and impact within these critical medical domains.

Major companies operating in the fertility drugs market include Merck & Co., Ferring Pharmaceuticals Inc., Bayer AG, Berlex Laboratories Inc., Janssen Pharmaceutical Inc., Pfizer Inc., Novartis AG, Procter & Gamble Health Limited, Zydus Lifesciences Limited, Livzon Pharmaceutical Group Inc., Abbott Laboratories, Sanofi S.A., Eli Lilly and Company, Serono Inc., Novagen Healthcare Pvt. Ltd., Takeda Pharmaceutical co. Ltd., AstraZeneca PLC, Aurobindo Pharma Ltd., Schering-Plough Corporation, Regeneron Pharmaceuticals Inc., Inovio Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., F. Hoffmann-La Roche AG, Alnylam Pharmaceuticals Inc., Argos Distributors Limited, Sarepta Therapeutics Inc., Moderna Inc., BioNTech SE, Biogen Inc.

North America was the largest region in the fertility drugs market in 2023. The Middle East is expected to be the fastest-growing region in the drugs for infertility market during the forecast period. The regions covered in the fertility drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa The countries covered in the fertility drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

These drugs fall into two main categories include prescription fertility drugs and over-the-counter variants. They are administered through various methods including oral ingestion, intravenous injection, subcutaneous injection (into the fatty tissue just below the skin), and intramuscular injection, catering to both male and female patients. Distribution channels for these drugs span hospital pharmacies, retail outlets, and online pharmacies, ensuring accessibility across different avenues for patients seeking fertility treatment.

The fertility drugs market research report is one of a series of new reports provides fertility drugs market statistics, including fertility drugs industry global market size, regional shares, competitors with a fertility drugs market share, detailed fertility drugs market segments, market trends and opportunities, and any further data you may need to thrive in the fertility drugs industry. This fertility drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The fertility drugs market consists of sales of clomiphene citrate, gonadotropins, and metformin. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.